Research
Metabolic adaptation
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.
Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.
StrongSupportsmedium confidence
MASLD prevalence reduced from 82.6% to 30.4% ( P < 0.001).
Why this rating
Based on the real-world study design with a significant sample size.
Source
Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes
Jonathan Mertens et al. · Diabetes Technology & Therapeutics · 2025
cohort · n=42Cited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →